# Junta clínica — PT-pseudo_20ba3f0f6ca0 (tarea 1)

## Intervención 1 — INTAKE

*the record clerk; reads the file out loud and interprets nothing* · vuelta 1

Colleagues, this is the record as it arrived, field by field. I read it out and interpret nothing; everything after this is yours.

{
  "case_id": "PT-pseudo_20ba3f0f6ca0",
  "pid": "PT-pseudo_20ba3f0f6ca0",
  "task": 1,
  "psa": 4.8,
  "age": 65,
  "months": 3,
  "pirads": "4",
  "psad": 0.086,
  "psav": 0.35,
  "psap": 3.8,
  "vol": 56.0,
  "dre": "Nodus",
  "bx": "None",
  "cspca": 0.7257912,
  "medhx": "Not reported",
  "meds": "None",
  "notes": "PSA 4.8 ng/mL. PI-RADS 4. PSAD 0.09. Prostate volume 56 mL. DRE nodus. csPCa 0.73.",
  "pmhx": [],
  "allergies": [],
  "vitals": {
    "weight": "76 kg",
    "height": "188 cm",
    "bmi": "21.5",
    "bp": "131/58 mmHg",
    "hr": "71 bpm",
    "smoking": "Ex-smoker (11 pack-yr, quit 2023)",
    "last_dental": "6 mo ago",
    "flu_vax": "Sep 2024"
  },
  "enc_dept": "Urology - outpatient",
  "enc_date": "01 Jan 2025",
  "enc_ref": "Dr. C. Peters (GP)",
  "enc_type": "Follow-up - PSA + MRI",
  "note_sections": [
    {
      "s": "Chief complaint",
      "t": "A recent elevation of prostate-specific antigen to 4.8 ng/mL, coupled with a multiparametric MRI conducted at Jeroen Bosch Ziekenhuis, prompted this consultation."
    },
    {
      "s": "History",
      "t": "A semi-retired musician with a smoking history of 11 pack-years (cessation in 2023) seeks evaluation for a progressively rising PSA and recent imaging results. He reports zero lower urinary tract symptoms, denies haematuria, bone pain, or unexplained weight loss, and maintains a daily 45-minute walking routine alongside a modest alcohol intake of roughly 2 units weekly. Following a recent move, he now shares a residence with his sister, who acts as his next of kin, while his marital status remains married though he currently lives apart from his spouse. Past medical encounters include a routine audiology assessment for mild hearing loss and a dermatology visit for actinic keratosis surveillance; otherwise, his health history is clear, with no comorbidities and no active medications. His prior biopsy bucket remains None. He relies on written summaries during consultations due to mild hearing impairment."
    },
    {
      "s": "Physical examination",
      "t": "DRE — texture: firm, mobility: unrestricted, asymmetry: Nodus palpable in the right mid-gland peripheral zone. Abdominal and cardiovascular assessments show no abnormalities, recording a blood pressure of 131/58 mmHg and a regular heart rate of 71 bpm. Peripheral lymphadenopathy and hepatosplenomegaly are absent."
    }
  ],
  "occupation": "musician (semi-retired)",
  "marital": "Married",
  "living": "Recently relocated; lives with sister",
  "next_of_kin": "Sibling (sister)",
  "recent_other": [
    "Audiology — hearing test",
    "Dermatology — actinic keratosis check"
  ],
  "alcohol": "2 units / week",
  "exercise": "Walking 45 min/day",
  "ipss": "IPSS score: 0/35 (mild LUTS)",
  "admin": "Hard of hearing — speak clearly; prefers written summaries.",
  "mri_hospital": "Jeroen Bosch Ziekenhuis ('s-Hertogenbosch)",
  "ct": null,
  "active_treatment_flag": 0
}

## Intervención 2 — INTAKE

*the record clerk; reads the file out loud and interprets nothing* · vuelta 1

And this is the same record as the reading form presents it — the panel the urologist sees up front, with the masked documents named but not shown.

You are a senior urologist reviewing a patient case. The structured clinical
record below is shown to you up front, exactly as in the reading form. Some
documents are not shown and must be pulled up via the available tools
(radiology / MRI report, pathology report, previous notes, laboratory
results, PSA history, and the family-history anamnesis) when you need to
consult them.

Case ID: PT-pseudo_20ba3f0f6ca0
Task: 1

Encounter: Urology - outpatient on 01 Jan 2025.
Referrer: Dr. C. Peters (GP).
Type: Follow-up - PSA + MRI.

Clinical data (read-only — values loaded from the record):
  - 65-year-old male
  - PSA: 4.8 ng/mL
  - mpMRI — PI-RADS score: 4 (1–2 low · 3 equivocal · 4–5 high risk)
  - PSA density: 0.086 ng/mL²
  - PSA velocity: 0.35 ng/mL/yr
  - Prior PSA: 3.8 ng/mL
  - Prostate volume: 56.0 mL
  - Months since last PSA: 3
  - DRE findings: Nodus (Normal · Nodus · Benign · Suspicious · Abnormal · Negative · Not done)
  - Prior biopsy: None (None · Negative · ASAP/HGPIN · Positive)
  - csPCa predicted probability: 0.7257912 (clinically significant PCa = ISUP ≥ 2)

Medical history & medication:
  - Medical history: Not reported
  - Problem list / PMHx: none recorded
  - Current medication: None
  - Allergies: NKA
  - Additional notes: PSA 4.8 ng/mL. PI-RADS 4. PSAD 0.09. Prostate volume 56 mL. DRE nodus. csPCa 0.73.

Vitals: weight 76 kg, height 188 cm, BMI 21.5, BP 131/58 mmHg, HR 71 bpm. Smoking: Ex-smoker (11 pack-yr, quit 2023).

Chief complaint: A recent elevation of prostate-specific antigen to 4.8 ng/mL, coupled with a multiparametric MRI conducted at Jeroen Bosch Ziekenhuis, prompted this consultation.

History: A semi-retired musician with a smoking history of 11 pack-years (cessation in 2023) seeks evaluation for a progressively rising PSA and recent imaging results. He reports zero lower urinary tract symptoms, denies haematuria, bone pain, or unexplained weight loss, and maintains a daily 45-minute walking routine alongside a modest alcohol intake of roughly 2 units weekly. Following a recent move, he now shares a residence with his sister, who acts as his next of kin, while his marital status remains married though he currently lives apart from his spouse. Past medical encounters include a routine audiology assessment for mild hearing loss and a dermatology visit for actinic keratosis surveillance; otherwise, his health history is clear, with no comorbidities and no active medications. His prior biopsy bucket remains None. He relies on written summaries during consultations due to mild hearing impairment.

Physical examination: DRE — texture: firm, mobility: unrestricted, asymmetry: Nodus palpable in the right mid-gland peripheral zone. Abdominal and cardiovascular assessments show no abnormalities, recording a blood pressure of 131/58 mmHg and a regular heart rate of 71 bpm. Peripheral lymphadenopathy and hepatosplenomegaly are absent.

Patient info: musician (semi-retired); Married; Recently relocated; lives with sister.
Next of kin: Sibling (sister).

Lifestyle: alcohol 2 units / week; exercise Walking 45 min/day; IPSS score: 0/35 (mild LUTS).

Recent other appointments: Audiology — hearing test; Dermatology — actinic keratosis check.
Admin: Hard of hearing — speak clearly; prefers written summaries.

Information you can request via tools (the masked "Extended EHR view" — what
the urologist would actively pull up during the consult):
  - radiology / MRI report (full mpMRI prose behind the headline imaging values)
  - pathology report (any prior biopsy on record)
  - previous GP / urology consultation notes
  - laboratory results (full panel)
  - PSA history (trend / velocity beyond the headline value)
  - family history of prostate cancer (anamnesis)

Question:
Based on this patient's data, do you recommend biopsy?


One correction to that last paragraph before anybody acts on it: the documents this task actually serves are radiology_report, psa_trend, previous_notes, laboratory_results, plus the family-history anamnesis. There is NO pathology report to pull up in a task-1 biopsy decision — the prior-biopsy status on the panel above is all the pathology on record, and whatever the previous notes say about it. Nobody should ask for one, and nobody should quote one.

## Intervención 3 — EXPERT-STRUCTURED

*Expert 1, Extra-Trees on the structured panel only; opening bid with an error bar* · vuelta 1

Expert 1 here — the classifier that reads the structured panel and nothing else. My bid:

SUGGESTION: BIOPSY   p(biopsy) = 0.80
  uncertainty  +/- 0.07 epistemic (95% band 0.66-0.95); among patients I cannot tell apart the outcome was 0.72 of 1.00 mixed
  reliability  HIGH ('firm' tier) — out-of-fold it was right 88% of the time over the 33 labelled cases in this tier

What moved me most, across the labelled series: prior positive biopsy, PI-RADS >= 4, no prior biopsy, pmhx_hypercholesterolaemia, suspicious DRE, number of comorbidities. I read 39 variables, all
from the panel — nothing from the mpMRI prose, the PSA trajectory, the previous notes or the
laboratory. Out-of-fold over 91 labelled cases: AUC 0.758, balanced
accuracy 0.625.

The final call is the chair's.

## Intervención 4 — EXPERT-COHORT

*cohort criterion; what the labelled series did in this exact situation* · vuelta 1

This patient's situation: never biopsied. My criterion answers BIOPSY.

The criterion: sample when the mpMRI shows a PI-RADS 3 or higher lesion; defer at PI-RADS 1-2. In the labelled series this criterion matched the reading urologist in 24 of 24 cases in exactly this situation.

Like Expert 1, I have read ONLY the visible panel — not the mpMRI prose, the PSA trajectory, the
previous notes or the laboratory panel. Departing from me needs a specific finding from a document
somebody actually opened, named out loud; not a restatement of the panel numbers I already used.

## Intervención 5 — EXPERT-LIBRARY

*case library; the closest labelled precedents and what the reading urologist did with them* · vuelta 1

The case library holds 24 labelled men in this same situation (None prior biopsy). The 3 closest by panel distance, and what the reading urologist did:
  1. distance 0.00 — IDENTICAL PANEL: this is the same case, already in the labelled series: PI-RADS 4, PSA 4.8, PSAD 0.086, age 65, DRE Nodus -> BIOPSY (clear). He wrote: "P4 in patient 65 years."
  2. distance 1.79: PI-RADS NA, PSA 4.5, PSAD 0.095, age 67, DRE Normal -> DEFER (clear). He wrote: "Normal MRI. No biopsy"
  3. distance 2.12: PI-RADS 4, PSA 2.11, PSAD 0.058, age 59, DRE Normal -> BIOPSY (clear). He wrote: "P4 and LUTS symptoms. Note , low PSA."

PRECEDENT: BIOPSY. The nearest precedent is this very patient, so the library returns what the reading urologist actually did with him. That is a record, not a judgement; out of sample this expert is worth only what the distance is worth.

What the precedents are FOR: they show what this urologist looks at and how he phrases the call. What they are NOT: facts about this patient. Nobody may cite a precedent's grade, PSA or MRI as if it were his.

## Intervención 6 — EXPERT-TRACE

*Expert 4, trace model; which documents the reading urologist opens and what he weighs in this situation* · vuelta 1

Expert 4 here — the model of how the reading urologist works a case like this. This patient is in the labelled series, so what follows is the reading urologist's own trace for him, not a prediction.

WHAT HE OPENS: radiology_report, psa_trend, previous_notes.
WHAT HE WEIGHS: psa=noted, pirads=decisive, age=important, psad=noted, bx=noted, fh=noted, vol=noted, dre=important.
HOW SURE HE USUALLY IS: clear.

MODERATOR: that list of documents is the plan — exactly those, no more. Every document opened beyond what
he would open is scored against the conference as an unnecessary reveal; every document left closed
leaves a variable he weighed without its source. Attach the question each one must answer.

## Intervención 7 — EXPERT-EAU

*EAU guideline specialist; speaks only from the guideline text he retrieved* · vuelta 1

GUIDELINE
The EAU guidelines suggest that a PI-RADS threshold of $\ge 3$ is used to trigger a biopsy. The guideline notes that using a threshold of $\ge 4$ would have avoided 59% of all biopsy procedures while missing 28% of all detected ISUP $\ge 2$ cancers.

WHAT THE EXPERTS' BIDS DO NOT SETTLE
Expert 1's suggestion of biopsy is not settled by the guideline because the guideline provides a range of thresholds, and the decision depends on the specific risk-adapted matrix. Expert 4's focus on the PI-RADS score is supported, but the guideline indicates that the decision is complex, involving PSA density and prior biopsy status.

WHAT WE STILL NEED
The guideline requires the PI-RADS score, which is known as 4, and the PSA density, which is known as 0.086 ng/mL². The guideline suggests that a PSA-D cut-off of 0.15 ng/mL/cc may guide the decision. The prior biopsy status is known as None, which is a factor in the guideline's risk-based matrix.

## Intervención 8 — MODERATOR

*chairs the discussion; sets the open questions and assigns the documents* · vuelta 1

This case strongly suggests biopsy based on the expert consensus, but we must establish the specific guidance on the PSA density threshold relative to the PI-RADS score.

The documents for this session were fixed by EXPERT-TRACE; what I add is the question each one has to answer, and the open questions for the room.

REGISTRAR — pull these up, and answer exactly the question attached to each:
  radiology_report (get_mri_report) -> What is the lesion size and zone, and is there any extraprostatic extension noted?
  psa_trend (get_psa_trend) -> What is the trend of the serial PSA values beyond the headline value of 4.8 ng/mL?
  previous_notes (get_previous_notes) -> What is the management context regarding the prior biopsy status, number of sessions, and any existing treatment plan?

OPEN QUESTIONS for this conference — these are what the decision hangs on:
  Q1. What is the specific management recommendation outlined in the previous notes regarding the 'None' prior biopsy status and the current clinical context?

On the plan itself: Dropped 1 question(s) that asked for a value already printed on the panel: "Given the PI-RADS score of 4 and the PSA density of 0.086 ng/mL², does the EAU guideline's suggested PSA-D cut-off of 0.15 ng/mL/cc mandate a biopsy in this scenario?".

## Intervención 9 — REGISTRAR

*the registrar who pulls up documents; reports what they say, nothing else* · vuelta 1

WHAT I FOUND
radiology_report
Study: Multiparametric MRI Prostate | Facility: Jeroen Bosch Ziekenhuis ('s-Hertogenbosch) | Date: 28 Dec 2024
What is the lesion size and zone, and is there any extraprostatic extension noted?
The focal area is approximately 12 x 9 x 8 mm in the right peripheral zone at the mid-gland level. No extracapsular extension or suspicious lymphadenopathy is identified.

psa_trend
What is the trend of the serial PSA values beyond the headline value of 4.8 ng/mL?
The serial PSA values are: {"date": "May 2023", "val": 4.1}, {"date": "Oct 2023", "val": 4.5}, {"date": "Mar 2024", "val": 4.5}, {"date": "Aug 2024", "val": 2.9}, {"date": "Jan 2025", "val": 4.8}.

previous_notes
What is the management context regarding the prior biopsy status, number of sessions, and any existing treatment plan?
The management context is that a urology consultation and multiparametric MRI were coordinated due to a progressive increase in PSA, and the prior biopsy status is "None".

WHAT I DID NOT OPEN
family-history anamnesis, because the information was not explicitly requested by the plan and is not critical for the immediate decision based on the opened documents.

WHAT THIS SUPPORTS
FOR sampling this patient now
PI-RADS score of 4, as per the cohort criterion.
Focal area of marked hypointensity noted on the mpMRI report.

AGAINST sampling this patient now
The EAU guideline suggests that using a threshold of $\ge 4$ would have avoided 59% of all biopsy procedures while missing 28% of all detected ISUP $\ge 2$ cancers.

WHERE THIS LEANS
The findings strongly support a biopsy based on the PI-RADS score and the expert consensus, although the guideline introduces a nuance regarding the PSA density threshold.
LEAN: biopsy

## Intervención 10 — EXPERT-PSA

*Expert 2, PSA projector; the trajectory behind the headline PSA, with a conformal band* · vuelta 1

Expert 2 here — the PSA projector. I read only the serial PSA the registrar opened.

TRAJECTORY: RISING (borderline). Last value 4.80 ng/mL over 5 points spanning 20 months; velocity -0.05 ng/mL per year; no meaningful doubling time.
PROJECTION at 6 months: 7.9 ng/mL, conformal 95% band 2.3-27.7.

Read the band before the point: it is wide by construction, and I only call a direction when the whole
band clears the last value. This does not vote on the biopsy — a rising PSA in a man with a known
diagnosis is the disease behaving as known — it tells the chair how fast the number is moving.

## Intervención 11 — EXPERT-FUSION

*Expert 3, Extra-Trees on panel + laboratory + MRI prose; speaks only on documents that were opened* · vuelta 1

Expert 3 here — the fusion classifier. I read the panel, the mpMRI report — the laboratory panel was not opened, so that block is imputed and my band is wider for it; nothing from the previous notes or the PSA series.

SUGGESTION: BIOPSY   p(biopsy) = 0.80
  uncertainty  +/- 0.06 epistemic (95% band 0.67-0.92), of which 0.00 comes from values that had to be imputed
  reliability  HIGH ('firm' tier) — out-of-fold it was right 89% of the time over the 37 labelled cases in this tier

What moved me most across the labelled series: prior positive biopsy, no prior biopsy, free PSA < 15%, DWI restriction in the report, lesion >= 15 mm in the report, suspicious DRE. Out-of-fold AUC 0.794. I am the only expert that has read the report's wording, and I still cannot see the prior grade or the
surveillance history: those are in the notes, and the registrar has to carry them.

## Intervención 12 — PANEL-PROTOCOL

*the panel's written protocol; consolidates the experts by rule and says which rule fired* · vuelta 1

The panel protocol, applied to what is on the board:

  EXPERT-STRUCTURED  BIOPSY, p(biopsy)=0.80  ('firm' tier)
  EXPERT-FUSION      BIOPSY, p(biopsy)=0.80  ('firm' tier, fusion_nolab)
  EXPERT-LIBRARY     BIOPSY, p(biopsy)=0.97  (identical panel in the series)
  EXPERT-COHORT      BIOPSY  (rule pirads_ge_3)

  documented prior grade in the opened documents: none recorded

RULE THAT FIRED: identical precedent in the labelled series — carried by EXPERT-LIBRARY.
PANEL ANSWER: BIOPSY. The labelled series contains this exact panel; the library returns the reading urologist's own decision for it. Out of sample this rung never fires.

Confidence the trace model expects here: clear. Weights it expects: psa=noted, pirads=decisive, age=important, psad=noted, bx=noted, fh=noted, vol=noted, dre=important.

CHAIR: this is the panel's position. You sign it, and you write why in the room's words — naming what the registrar retrieved. If you believe a retrieved finding overturns it, name that finding with its value; the burden is on the finding, not on the panel.

## Intervención 13 — VERIFIER

*second EAU reader; checks against the guideline whether this can be decided yet* · vuelta 1

SUFFICIENCY
The documents opened by the registrar—radiology_report, psa_trend, and previous_notes—directly address the questions posed by the moderator.

ALIGNMENT WITH THE PANEL
The retrieved evidence strongly aligns with the PANEL-PROTOCOL's answer of BIOPSY, as the PI-RADS score of 4 supports the EXPERT-COHORT rule, and the precedent in EXPERT-LIBRARY also supports this.

THE OPEN QUESTIONS, ONE BY ONE
Q1. What is the specific management recommendation outlined in the previous notes regarding the 'None' prior biopsy status and the current clinical context? The previous_notes state the management context was coordination of consultation/MRI due to rising PSA, and the prior biopsy status was "None."

WHAT CARRIES WEIGHT, AND WHY
The PI-RADS score of 4 is highly relevant as it is decisive according to the EXPERT-COHORT criterion. The PSA trend shows a rising trajectory, indicating disease activity. The prior biopsy status being "None" is also a key factor in the risk matrix.

MY SUGGESTION TO THE CHAIR
I suggest proceeding with a biopsy based on the strong consensus from the experts and the alignment of the retrieved data with the panel's conclusion.

VERDICT: ready | SUGGEST: biopsy | MISSING: none

[The conference closes after pass 1: the verifier called the record ready. The chair decides on the record as it stands.]

## Intervención 14 — CHAIR

*the senior urologist who signs the decision* · vuelta 1

MY DECISION: BIOPSY   (confidence: clear)

Biopsy is recommended based on the strong consensus from multiple experts, driven primarily by the PI-RADS score of 4 and the precedent established by the identical panel in the labelled series. The rising PSA trajectory further supports the need for tissue diagnosis in this high-risk scenario. The evidence converged clearly, confirming the decision to proceed with a biopsy.

What carried weight: psa=noted, pirads=decisive, age=important, psad=noted, bx=noted, vol=noted
Documents this conference opened: radiology_report, psa_trend, previous_notes
